Research in Social and Administrative Pharmacy
Volume 2, Issue 1 , Pages 143-151 , March 2006

Addressing the issue of channeling bias in observational studies with propensity scores analysis

  • Francis S. Lobo, B.Pharm., M.S., Ph.D.

      Affiliations

    • Health Economics & Outcomes Research Group, East Hanover, NJ 07936, USA; Novartis Pharmaceuticals, College of Pharmacy, University of Minnesota, MN 55455, USA
    • Corresponding Author InformationCorresponding author: One Health Plaza, East Hanover, NJ 07936, Tel.: 862 778 5218, Fax: 973 781 2439.
    • ,
  • Samuel Wagner, R.Ph., Ph.D.

      Affiliations

    • Customer Outcomes Research Group, Pfizer Inc, New York, NY 10017, USA
    • ,
  • Cynthia R. Gross, Ph.D.

      Affiliations

    • Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, MN 55455, USA
    • ,
  • Jon C. Schommer, R.Ph., M.S., Ph.D.

      Affiliations

    • Graduate Studies in Social and Administrative Pharmacy, College of Pharmacy, University of Minnesota, MN 55455, USA

References 

  1. Collet J, Boivin J. Bias and confounding in pharmacoepidemiology. In:  Strom BL editors. Pharmacoepidemiology. Chichester, West Sussex, England: John Wiley & Sons Ltd; 2000;
  2. Feinstein AR. Clinical Epidemiology. Philadelphia, Pa: Saunders; 1985;
  3. Urquhart J. ADR crisis management—before and after. Scrip. 1989;1388:19–21
  4. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10:577–581
  5. Petri H, Naus J, Urquhart J. Channeling of aerosol beta agonist and the interpretation of a concomitant adverse event. J Clin Res Drug Dev. 1989;3:224–230
  6. Inman WH. Comparative study of five NSAIDs. PEM News. 1985;3:3–13
  7. O'Donnell TV, Rea HH, Holst PE, et al. Fenoterol and fatal asthma. Lancet. 1989;1:1070–1071
  8. Spitzer WO, Buist AS. Case-control study of prescribed fenoterol and death from asthma in New Zealand. Thorax. 1990;45:645–646
  9. Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol. 1996;144:1161–1169
  10. Wolfe F, Flowers N, Burke TA, et al. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol. 2002;29:1015–1022
  11. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–763
  12. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55
  13. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–333
  14. Connors AF, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA. 1998;18:889–897
  15. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281
  16. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate a propensity score. Am Stat. 1985;39:33–38
  17. Stone RA, Obrosky S, Singer DE, Kapoor WN, Fine MJ. Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community acquired pneumonia. Med Care. 1995;33:AS56–AS66
  18. Perkins SM, Tu W, Underhill MG, Zhou X, Murray MD. The use of propensity scores in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2000;9:93–101
  19. Hylan TR, Crown WH, Meneades L, et al. TCA and SSRI anti-depressant selection and health care costs in naturalistic setting: a multivariate analysis. J Affect Disord. 1998;47:71–79
  20. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health. 1998;19:17–34
  21. Rubin DB. On principles for modeling propensity scores in medical research. Pharmacoepidemiol Drug Saf. 2002;13:855–857
  22. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction reduce mortality?. JAMA. 1994;272:859–866
  23. McClellan M, Newhouse JP. The marginal costs and benefits of medical technology: a panel instrumental-variables approach. J Econ. 1997;77:39–64
  24. Zohoori N, Savitz DA. Econometric approaches to epidemiologic data: relating endogeneity and unobserved heterogeneity to confounding. Ann Epidemiol. 1997;7:251–257

PII: S1551-7411(05)00130-0

doi: 10.1016/j.sapharm.2005.12.001

Research in Social and Administrative Pharmacy
Volume 2, Issue 1 , Pages 143-151 , March 2006

Article Tools